Literature DB >> 27387226

Efficacy and safety of ketamine in bipolar depression: A systematic review.

Susana Alberich1, Mónica Martínez-Cengotitabengoa2, Purificación López3, Iñaki Zorrilla3, Nuria Núñez1, Eduard Vieta4, Ana González-Pinto5.   

Abstract

The depression is the most prevalent state throughout the life of the bipolar patient. Ketamine has been shown to be an effective and rapid treatment for depression. The objective of the present work is to perform a systematic review on the efficacy and safety of ketamine as treatment of bipolar depression, as well as its different patterns of administration. The search found 10 relevant manuscripts that met the inclusion criteria: one clinical trial, 5 cohort studies, and 4 case reports. Intravenous infusion was used in 60% of the studies. According to data, ketamine seems to be an effective and safe treatment for bipolar depression, although the length of its effect is short. Adverse effects observed generally occurred at the time of infusion, and tended to completely disappear within 1-2h. Therefore, more studies are necessary to explore new patterns of administration, as well as on its safety and adverse effects.
Copyright © 2016 SEP y SEPB. Publicado por Elsevier España, S.L.U. All rights reserved.

Entities:  

Keywords:  Bipolar depression; Depresión bipolar; Efficacy; Eficacia; Ketamina; Ketamine

Mesh:

Substances:

Year:  2016        PMID: 27387226     DOI: 10.1016/j.rpsm.2016.05.005

Source DB:  PubMed          Journal:  Rev Psiquiatr Salud Ment        ISSN: 1888-9891            Impact factor:   3.318


  7 in total

1.  Ketamine for Bipolar Depression: Biochemical, Psychotherapeutic, and Psychedelic Approaches.

Authors:  Raquel Bennett; Christian Yavorsky; Gary Bravo
Journal:  Front Psychiatry       Date:  2022-05-23       Impact factor: 5.435

Review 2.  Ketamine and other glutamate receptor modulators for depression in adults with bipolar disorder.

Authors:  Rebecca L Dean; Tahnee Marquardt; Claudia Hurducas; Styliani Spyridi; Annabelle Barnes; Rebecca Smith; Philip J Cowen; Rupert McShane; Keith Hawton; Gin S Malhi; John Geddes; Andrea Cipriani
Journal:  Cochrane Database Syst Rev       Date:  2021-10-08

3.  Population scale data reveals the antidepressant effects of ketamine and other therapeutics approved for non-psychiatric indications.

Authors:  Isaac V Cohen; Tigran Makunts; Rabia Atayee; Ruben Abagyan
Journal:  Sci Rep       Date:  2017-05-03       Impact factor: 4.379

4.  Population scale retrospective analysis reveals distinctive antidepressant and anxiolytic effects of diclofenac, ketoprofen and naproxen in patients with pain.

Authors:  Tigran Makunts; Isaac V Cohen; Kelly C Lee; Ruben Abagyan
Journal:  PLoS One       Date:  2018-04-18       Impact factor: 3.240

5.  Comparative Effect of Intravenous Ketamine and Electroconvulsive Therapy in Major Depression: A Randomized Controlled Trial.

Authors:  Gholamreza Kheirabadi; Maryam Vafaie; Dorna Kheirabadi; Zahra Mirlouhi; Rasam Hajiannasab
Journal:  Adv Biomed Res       Date:  2019-04-10

6.  Ketamine for Bipolar Depression: A Systematic Review.

Authors:  Anees Bahji; Carlos A Zarate; Gustavo H Vazquez
Journal:  Int J Neuropsychopharmacol       Date:  2021-07-23       Impact factor: 5.176

Review 7.  Ketamine for the treatment of mental health and substance use disorders: comprehensive systematic review.

Authors:  Zach Walsh; Ozden Merve Mollaahmetoglu; Joseph Rootman; Shannon Golsof; Johanna Keeler; Beth Marsh; David J Nutt; Celia J A Morgan
Journal:  BJPsych Open       Date:  2021-12-23
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.